masivet
ab science s.a. - masitinib mesilate - antineoplastic agents - dogs - treatment of non-resectable dog mast-cell tumours (grade 2 or 3) with confirmed mutated c-kit tyrosine-kinase receptor.
digifab digoxin-specific antibody fragment f(ab) (ovine) 40mg powder for injection vial
phebra pty ltd - digoxin-specific antibody fragment f(ab) (ovine), quantity: 40 mg - injection, powder for - excipient ingredients: mannitol; sodium acetate - digoxin-specific antibody fragment f(ab) (ovine) digifab is indicated for the treatment of known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias, progressive bradycardia, or second or third degree heart block not responsive to atropine, and where additional measures besides withdrawal of digoxin and correction of serum electrolyte abnormalities are considered necessary. consequences of multiple dosing with digifab have not been evaluated.
ab - colic suspension oral en gotas
marketing & distribution pharma, s.a. (m&d pharma) - cepas ab-colic* - cepas ab-colic*....32,00 mg (1x10^9 ufc)
ab cid liquid
ab pharmaceuticals (ayurvedic) - amalaki rasayan - liquid
ab card liquid
ab pharmaceuticals (ayurvedic) - arjunarista - liquid
ab cough liquid
ab pharmaceuticals (ayurvedic) - draksharista - liquid
alsitek
ab science - masitinib mesilate - amyotrophic lateral sclerosis - antineoplastic agents - treatment of amyotrophic lateral sclerosis.
masipro
ab science - masitinib mesilate - mastocytosis - antineoplastic agents - treatment of mastocytosis
masiviera
ab science - masitinib - pancreatic neoplasms - protein kinase inhibitors - treatment of non resectable locally advanced or metastatic pancreatic cancer